Received more than 11 times oversubscription, TWI successfully listed on the main board of Taiwan Gretai Securities Market (“GTSM”)

Dec 3, 2013

TWI Pharmaceuticals, Inc, (“TWI” or “the Company”) (Bloomberg Ticker: 4180TT), a leading specialty pharmaceutical company, has successfully transferred from the emerging board and listed on the main board of Taiwan Gretai Securities Market (“GTSM”). The listing of TWI received more than 11 times oversubscription to the issuance of 12.9 million new shares with approximately NTD3.3 billion of capital raised.

Read more X

Closes oversubscribed US$ 100M fund, with 50% GP commitment - The CID Group Completes Greater China Fund IV fundraising

Aug 16, 2013

The CID Group today announced the first and only close of CID Greater China Fund IV (“Fund” or “CID IV”). The Fund is a successor fund to the US$400M CID Greater China Venture Capital Fund III. The Firm kicked off the fundraising in March, and received over US$ 425M demand from both existing and new investors within less than 4 months. With goals to better align GP-LP interests and to deliver superior returns, the general partners worked closely with the limited partners and several pipeline investments’ management teams, and devised an innovative structure in which the GP will commit 50% of the new fund and finalize the fund size at US$100M.

Read more X

Amazing trading 45% above the listing price, listed on Taiwan Emerging Stock Market

Dec 26, 2012

Listed on Taiwan Emerging Stock Market (Bloomberg Ticker: 6411 TT) on December 25th, 2012, the trading price of the Company surged 45% above the listing price, NT$55 (US$1.89) on the day it debuted, and closed at NT$60.5 per share (US$2.08), with closing market cap of NT$2.17 billion.

Read more X